Friday, April 21, 2023
1:00 – 6:00 pm
Registration Open
2:00 – 2:50 pm
ASHP Practice Advancement Initiative (PAI) 2023
Presented by Lam Nguyen, PharmD, MBA, Long Trinh, PharmD, MS, MBA, BCPS, and Jessica Hendrix, PharmD
Since is inception in 2010, ASHP’s Practice Advancement initiative (PAI) has resulted in a remarkable partnership with ASHP state affiliates, health systems, and pharmacists to help drive pharmacy practice change at a local level. Join us to discuss Oregon’s preliminary self-assessment survey results and how your practice setting aligns with the PAI 2030 recommendations.
3:00 – 3:50 pm
Troubleshooting & Strategies to Manage/Develop Students & Residents
Presented by Sue Stein, DHEd, MS, BS Pharm, RPh, FNAP, FOSHP and Dana Hammer, RPh, MS, PhD
This interactive workshop engages participants in discussions about situations that they find most challenging when precepting students and residents, and helps them to create strategies to prevent and mitigate those challenges.
3:50 – 4:10 pm
Break
4:10 – 5:00 pm
Poster to Podium Session
-
Antibiotic Modifications and Health Care Utilization Outcomes among Patients Prescribed Antibiotics on Discharge from the Hospital to Nursing Homes
Presented by Michelle Zhou, PharmD Candidate
Approximately half of antibiotics in nursing homes are initiated in acute care hospitals. However, little is known regarding outcomes associated with these antibiotics following nursing home admission. In this presentation, we describe a retrospective cohort study in which we quantified antibiotic modifications and health care utilization outcomes among patients prescribed antibiotics on discharge from the hospital to nursing homes.
-
Communication Regarding Opioid Prescriptions Among Patients Discharged from the Hospital to Nursing Homes
Presented by Evita Santos, PharmD Candidate 2023
Opioid use is prevalent among nursing home residents and previous studies suggest that nursing home residents are at an increased risk of under treatment of pain. Clear communication regarding these prescriptions is critical to optimize opioid management and minimize opioid related harms. In this presentation, we describe a retrospective cohort study in which we quantified the frequency of missing communication regarding opioid prescriptions among patients discharged from the hospital to a nursing home.
-
Hepatitis C Program Outcomes
Presented by Jenn Stanislaw, PharmD, BCACP
Treatment of Hepatitis C Virus in a primary care setting with direct acting antivirals (DAAs) has been increasing in frequency over the last several years. This project describes the Hepatitis C treatment program at an urban federally qualified health center, patient population, and subsequent treatment outcomes. Results have shown that successful treatment rates are similar to those reported in the literature for the general United States population.
-
VIONE Methodology
Presented by Eric Okzazki on behalf of Shannon O'Leary
The implementation of the VIONE methodology can be utilized to drive deprescribing of inappropriate or unnecessary medications leading to improved medication adherence, fewer adverse drug reactions and reduced financial costs. Strategies to prevent drift are needed to ensure perpetration of new processes and workflows.
5:00 – 6:00 pm
Welcome Reception with Exhibitors
Join fellow OSHP attendees for this fun event featuring great food and drink, and even better networking. Don’t miss this opportunity to catch up with old friends and meet new ones from across the region.
Saturday, April 22, 2023
7:00 am – 5:30 pm
Registration Open
7:00 - 8:00 am
Gary Clausen Memorial 2-mile Run/Walk (optional)
We challenge you to dig out your running shoes and headbands and wake-up with us with a short run (or walk) ! This free event is for all OSHP Annual Seminar attendees and honors Gary Lee Clausen, a former OSHP President and avid runner who repeatedly won this annual event. Prizes will be awarded to the top male and female finishers (but don’t let that keep you from running)! Start your Saturday morning off right and get energized for a fun filled day of learning and networking *Please indicate by name above if any are under the age of 13 years. Pre-registration is required.
8:00 - 8:30 am
Continental Breakfast with Exhibits
8:00 - 8:30 am
Annual Seminar Welcome & Orientation Session
New to OSHP? First time attendee? Join us for an overview of the seminar schedule, explore the seminar app, meet the staff and OSHP leadership. Hear from OSHP experts about the various tracks and what you can expect during evening events as we welcome you into the OSHP family.
8:30 - 9:30 am
Keynote Presentation: Addressing Health Disparities in Health Systems
Keynote presented by Marie Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, FACHE
Keynote Panel to Discuss Oregon's Impact: Dave Bearden, Dan Rackham, PharmD, BCPS and Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
Health systems must address barriers to healthcare access that contribute to health disparities. Join this session to learn about social determinants of health (SDOH), mental health services, and workforce and leadership diversity. Learn how to drive change from awareness to action.
9:30 - 9:45 am
Break with Exhibitors
9:45 - 10:35 am
Advocating for our Practice: The 2023 OSHP LRAC Agenda (General Session)
Presented by Andrew Albanese, PharmD, MBA and Cassandra R. Robertson-Binkley, PharmD, MBA
Presenting the good, the bad, and the ugly of OSHP LRAC's legislative work during the past year. Success and set-backs to OSHP legislative work will be discussed. The presentation will also review the work that went into creating HB 2015 and HB 2016 and where the bills are today
10:40 - 11:20 am
OSHP Section Networking
Meet and network with colleagues who share your professional interests. Sections include Ambulatory Care, Management, Informatics/Technology/Research, Inpatient Practitioners/Clinical Specialists.
10:40 am - 12:00 pm
Networking with Exhibitors
Enjoy time with Exhibitors where you can learn about the latest in industry trends. This opportunity provides a personal networking experience where you can meet face to face with suppliers who are there to support and connect with Pharmacy Professionals.
11:00 am – 12:00 pm
Poster Session
Network with colleagues, learn about practice changes and share results of new initiatives during the judged poster display. Prizes are offered for students and resident/practitioner categories – stop by and support the efforts.
12:00 – 1:00 pm
Networking Lunch
1:15 - 2:05 pm
The Pharmacist's Role in Caring for People with Intellectual and Developmental Disabilities (General Session)
Presented by Rebekah Fettkether, Special Olympics
This session is indented to introduce pharmacists, pharmacy technicians, and student pharmacists to working with people with intellectual and developmental disabilities (IDD). The presentation will increase awareness of the needs and overall health disparities of people with IDD, provide education on the biases surrounding the care of people with IDD, and discuss skills and strategies that pharmacists can use to increase their confidence in caring for this population.
2:05 - 2:20 pm
Break
2:20 - 3:10 pm
Alzheimer's Disease and Dementia Treatment Update (Track A)
Presented by Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
Alzheimer’s disease (AD) is the most common cause of dementia. The biggest risk for development of AD is advanced age, therefore due to increased population of 60 years and older there is a growing need for competency in management of this disorder across the entire clinical continuum from community pharmacy, ambulatory care, general medicine to specialty neurologic and geriatric care. All practitioners should be competent in providing care and making therapeutic recommendations for patient and caregiver counseling. This session will provide solid foundations and useful clinical information immediately applicable to care for persons with AD and will be provided in the form of longitudinal case.
2:20 - 3:10 pm
Recent Literature you May Have Missed (Track B)
Presented by Craig Williams, PharmD, BCPS, FNLA and John Begert, PharmD, BCACP
During this presentation the audience will learn the important take away points about 2 important clinical trials recently published. Context for the trials will be presented along with clinically relevant points that can be immediately applied to clinical practice.
3:15 - 4:05 pm
Common myths in Antibiotic Stewardship (Track A)
Presented by James Lewis III, Pharm D, FIDSA
Myths in medicine are everywhere, particularly in the antibiotic space. This presentation will cover commonly stated beliefs about antibiotic therapy that are not well supported by literature and will discuss recent literature that helps dispel these myths.
3:15 - 4:05 pm
Supporting Learning Experiences Through Prioritizing Open Communication and Professional Identity Formation (Track B)
Presented by Brandon Nuziale, PharmD, BCACP and Maddie Fry, PharmD, BCACP
The session will discuss some practical tools in designing your learning experience emphasizing the value of setting clear expectations with the ultimate goal of creating a collaborative, transparent learning environment that allows learners to grow and begin to define their own professional identities.
4:10 - 5:00 pm
Clapping the Clap: Sexually Transmitted Infection Management Review and Update
Presented by YoungYoon Ham, PharmD, BCIDP
This presentation will be a review of a variety of STIs, and their treatments. There will be an emphasis on official updates and some new primary literature that may not have made it into guidelines yet but might be clinically useful. Also will touch on the role that pharmacists can play in treating these infections as well as increasing screening.
4:10 - 5:00 pm
Pharmacy Trivia
Presented by Jessica Potter, PharmD
This will be an interactive, team-based jeopardy game to help refresh a broad variety of pharmacy topics. The answer submissions will be electronic followed by reviews of each answer to help us all learn together. Topics will vary from over-the-counter medications, new drugs, acute care topics, and much more!
6:00 – 6:30 pm
Reception, Silent Auction and Wall-of-Wine
Come join us for our “Not-So-Silent” auction! Bidders “silently” add their names and bid amounts to items they are interested in, while the MC keeps things lively with periodic announcements of good deals and items moving quickly. Not your style? Go to the “Wall-of-Wine” and bid on concealed bottles of wine. What is their value? You may be pleasantly surprised! Both benefit the OSHP Scholarship Fund for students and PAC, respectively. Auction purchases may be tax deductible to the extent that the purchase price exceeds fair market value of the item purchased.
6:30 - 9:00 pm
Dinner and Awards
Sunday, April 24, 2022
7:30 – 8:15 AM
Breakfast
7:00 – 8:00 AM
President’s Council Breakfast
8:00 – 10:00 am
Clinical Pearls
Join us for a fast paced clinical pearls session where pharmacy colleagues will provide quick practical tips, ideas or facts that will be useful in everyday practice.
Illicit Fentanyl: Navigating the Unknown
Presented by E.J. Pickels
National data comparing opioid overdose trends between 2020 to 2021 show that illicit fentanyl is now responsible for almost half of reported opioid overdoses. The trend has shifted from heroin causing more than half of reported opioid doses to now a majority being caused by fentanyl. This shift leaves healthcare providers with numerous questions regarding how to appropriately treat these emergencies, as many do not respond to the traditional doses of naloxone for reversal.
In addition to unknown drug concentrations within the products, illicit fentanyl may also contain xylazine, a central alpha-2 agonist used to enhance euphoric effects. Xylazine is not reversed by naloxone and may be contributing to the increased number of fentanyl-related deaths.
The impure nature of illicitly manufactured fentanyl may change what we know about opioid reversal practices with naloxone. Recently published data suggest a trend that higher doses of naloxone are required to reverse illicit fentanyl overdoses. However, the data is inconsistent in the doses of naloxone required. Studies also vary in design, patient population, knowledge of the overdose event, and administration route of naloxone for reversal. With the available data, it is difficult to ascertain appropriate treatment doses in these events.
Knowledge of fentanyl pharmacokinetics and potential variations due to impure manufacturing and differing routes of administration can assist practitioners in recognizing the potential need for increased naloxone requirements.
In-clinic transition of buprenorphine for opioid use disorder (OUD)
Presented by R.P. Gandhi
On December 29, 2022, the Consolidated Appropriations Act of 2023 was signed and eliminated the “DATA-Waiver Program.” The removal of X-waiver status for buprenorphine prescribing for opioid use disorder (OUD) not only removes maximum patient requirements, but also allows access for all providers with a Drug Enforcement Administration (DEA) license to prescribe buprenorphine for OUD. Clinical pharmacists with a DEA license and scope of practice can work to eliminate stigma, increase medication adherence, and monitor adverse symptoms by initiating and monitoring buprenorphine for patients with OUD. Baseline knowledge of in-clinic transitions to buprenorphine should be completed to understand common transition protocols. By achieving mastery of this common practice, clinical pharmacists will be an excellent resource in helping treat OUD.
Doxepin for treatment of insomnia in elderly adults
Presented by T.L. Do
Treatment options for insomnia in the elderly population are limited as this population is at higher risk for worrisome side effects related to sedating sleep medications. Although data is limited in elderly adults, one treatment option with moderate-high level of evidence for efficacy is doxepin. Studies have shown that doxepin up to 6mg and up to 3 months is superior to placebo in regard to sleep parameters. Doxepin exerts its effect through histamine-1 (H1) receptor antagonism and, at lower doses (<7mg/day), has a safety profile comparable to placebo eliminating concern for anticholinergic side effects. Doxepin’s demonstrated effects and favorable safety profile is why it is considered a first line agent for the treatment of insomnia in elderly adults.
Treatment of Resistant Hypertension
Presented by A.M. Proteau
Resistant hypertension is defined as having a blood pressure that remains above goal despite the use of three antihypertensive agents from different classes taken at maximally tolerated doses, including a diuretic. In patients with resistant hypertension, there are various strategies to help lower blood pressure. The first step is to identify and treat secondary causes contributing to hypertension, such as obstructive sleep apnea, primary aldosteronism, or renal artery stenosis. For pharmacologic therapy progression, there are multiple options which should be tailored to the specific patient. The current diuretic can be switched to a more potent diuretic, such as chlorthalidone or a loop diuretic like torsemide if the eGFR < 30 mL/min/1.73 m2. Another possibility is to add a mineralocorticoid receptor antagonist (MRA), like spironolactone, in additions to the current three agents. If further blood pressure lowering is needed after the patient is already on an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), a thiazide-like diuretic, and a MRA, an agent from a different class should be initiated. A nonselective, vasodilating beta blocker such as carvedilol can be added. Other medication options include centrally acting agents that lower sympathetic activity like clonidine or guanfacine, alpha-1 antagonists like doxazosin, or direct vasodilators like hydralazine. Treating resistant hypertension should be a multidisciplinary approach, consisting of pharmacologic and non-pharmacologic therapy and interventions.
Antibiotic use in asymptomatic bacteriuria (ASB)
Presented by Y.B. Ly
Asymptomatic bacteriuria (ASB) is common and increases with age, genitourinary abnormalities, and long-term indwelling catheter use. Inappropriate antibiotic prescribing for ASB, especially in older adults, remains prevalent in clinical practice despite guideline recommendations to refrain from treating ASB. The treatment of ASB is associated with adverse side effects, drug interactions, Clostridioides difficile infections, and the development of resistant organisms causing future urinary tract infections (UTIs). There is a lack of benefit with antibiotic treatment of ASB in most patients with a few exceptions. ASB treatment should be reserved for pregnant patients and patients undergoing urologic procedures associated with mucosal trauma.
Keeping up with the changes: an overview of the major updates to the 2023 GOLD Guidelines for COPD Management
Presented by Jessica Merlo
The Global Initiative for Chronic Lung Disease (GOLD) publishes annual updates to its guidelines for the management of COPD. In most recent years, the majority of updates had been minor or not applicable to practicing pharmacists. However, the 2023 guidelines have brought about significant changes to initial classification and grouping, which in turn have impacted the therapy recommendations for initial treatment. Most notably, combination therapy, with long-acting beta agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), has an increased role in initial treatment due to enhanced symptom and exacerbation control when compared to monotherapy of either. Additionally, the role of inhaled corticosteroids (ISC) remains well defined with increasing evidence to support the use of blood eosinophil levels when evaluating the appropriateness of ICS therapy. With COPD reaching the status of the 3rd leading cause of death in the world, it has become critical to ensure proper management of the disease. Application of the 2023 GOLD guidelines will allow for optimization of therapy and is an area where pharmacists can make impactful interventions.
